Addressing Treatment Disparities to Reduce Risk and Improve Cardiovascular Outcomes Among Women and People of Color:
A Spotlight on LDL-C Lowering.


Erin D. Michos, MD, MHS

Associate Director of Preventive Cardiology
Division of Cardiology
Johns Hopkins University School of Medicine Co-Editor in Chief of the American Journal of Preventive Cardiology

Keith C. Ferdinand, MD, FACC, FAHA , FASPC, FNLA

Gerald S. Berenson Endowed Chair in Preventative Cardiology Professor of Medicine
John W. Deming Department of Medicine Tulane University School of Medicine

Program Overview

Cardiovascular diseases (CVDs) remain a formidable global health challenge, claiming a significant portion of lives annually and imposing substantial economic burdens. Despite advancements in treatment and prevention, persistent disparities in awareness and access to care disproportionately affect women and individuals from diverse racial and ethnic backgrounds. This initiative aims to address these gaps by providing healthcare professionals with updated educational resources and insights from ongoing clinical trials to optimize prevention and treatment strategies.

Target Audience

This educational initiative is designed for healthcare professionals who provide primary prevention services to patients with dyslipidemia, including primary care clinicians (physicians, physician assistants, nurse practitioners), cardiologists, lipid specialists, endocrinologists and diabetologists.

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Apply the clinical trial data, guidelines and new indications for the use of non-statin treatments in appropriate patients.
  • Discuss shared decision-making strategies when counseling women and patients from various racial/ethnic populations on appropriate lipid-lowering therapies to reduce their risk of ASCVD.


Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Iridium Continuing Education (Iridium). Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must
  • Read the learning objectives and faculty disclosures Complete the pretest
  • View the broadcast
  • Complete the posttest with a score of 100% or higher

A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.

Fee Information and Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or


Disclosures of Relevant Financial Relationships

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Consulting Fee (e.g., Advisory Board): Angiowave, Bayer, Boehringer Ingelheim, Broadview Ventures, CellProthera, Cereno Scientific, Hims, Janssen, McKinsey, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, SFJ, Stasys, Youngene
Contracted Research (Principal Investigators must provide information, even if received by the institution): Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, CSI, Eisai, Endotronix, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, Philips, PLx Pharma, Recardio, Regeneron, Roche, Sanofi, SpectraWAVE, Stasys, St. Jude Medical (Abbott), Svelte, The Medicines Company, Youngene, Vascular Solutions, 89Bio
Honoraria: CSL Behring, MJH Life Sciences
Stock Shareholder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed): Bristol Myers Squibb
Stock Option Holder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed): Angiowave, DRS.LINQ
Other: Board of Directors: Angiowave, Bristol Myers Squibb, DRS.LINQ
Data Monitoring Committees: Acesion Pharma, Boston Scientific, Novartis
Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon)

Erin D. Michos, MD, MHS
Consulting Fee (e.g., Advisory Board): Amgen, AstraZeneca, Boehringer Ingelheim, Edwards Lifescience, Esperion, Medtronic, Merck, Novartis, Novo Nordisk, New Amsterdam, Pfizer

Keith C. Ferdinand, MD
Consulting Fee (e.g., Advisory Board): Eli Lilly, Amgen, Novartis, Janssen, Boehringer Ingelheim

Kevin C Maki, PhD
Consulting Fee (e.g., Advisory Board): 89Bio, Beren Therapeutics, Eli Lilly and Company, Matinas Biopharma Holdings, Inc., New Amsterdam Pharma, Northsea Therapeutics
Contracted Research (Principal Investigators must provide information, even if received by the institution): Beren Therapeutics, Eli Lilly and Company, Matinas Biopharma Holdings, Inc., New Amsterdam Pharma

The following planners and managers involved in the development of this activity have no relevant financial relationships with ineligible companies to disclose.

The planners and managers at Global Education Group have no relevant financial relationships to disclose.

Iridium staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Iridium do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is jointly provided by Global Education Group and Iridium Continuing Education.


This educational activity is supported by an independent educational grant from Esperion.

Maximum Credit Amount: 1.50
Credit Type: AMA
Release: May 15, 2024
Expiration: May 15, 2025